AdvaMed® Comments to HHS Deregulation RFI
AdvaMed® submitted public comments in response to HHS’s request for information on eliminating federal regulations that hinder economic growth, innovation, and American competitiveness.
Legal
Learn more about our Legal work.
AdvaMed® Response to House Privacy Working Group RFI
AdvaMed® calls for federal privacy laws that reflect how medical devices use patient data differently from consumer health tools.
AdvaMed® Comments to OMB Deregulation RFI
A powerful op-ed from AdvaMed’s CEO explaining why tariffs could undermine U.S. medtech innovation, jobs, and patient care—and what must be done.
MedTech Compliance Bootcamp
JoinAdvaMed® & Porzio for this comprehensive compliance bootcamp to better understand the current medtech compliance framework.
U.S. National Security & Business: Navigating Sanctions, Export Controls, CFIUS, and Outbound Investment Under the Trump Administration
Akin will provide a CLE program covering the latest legal issues for inbound trade and investment, including the Trump Administration’s approach to trade policy and tariff issues, and strategies medical…
The Medical Innovation Agenda for the 119th Congress
AdvaMed®’s medtech priorities for the 119th Congress highlight opportunities to address the most important issues facing patients and the medical technology industry today.
Smith v. Terumo BCT (Colorado Court of Appeals) March 6, 2025
AdvaMed® filed an amicus brief in the case of Smith v. Terumo BCT, Inc. The case concerns whether the court should create a cause of action for asymptomatic plaintiffs, permitting…